Danaher: Undervalued Healthcare Giant?

Danaher, a healthcare giant, has faced challenges post-COVID, with sales declines and investor sentiment soured. However, recent developments indicate a turnaround. Revenue has started climbing, and the acquisition of Masimo for $9.9 billion adds pulse oximetry tech, boosting sales and EBITDA. The first quarter of 2023 showed strong earnings growth, and analysts project 8-9% annual growth ahead. Despite being 36% below its all-time high, Danahers proven track record and current valuation make it an attractive buy for patient investors. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/efccc90246c96301